Keywords
How to Cite
Abstract
Pediatric non Hodgkin lymphoma is the third cause of pediatric cancer. We present the experience in our institution between January 2000 and May 2013, with 67 patients who completed 1LNHP 2000 GATLA Trial. The mean follow up was 69 m (r: 0.33 m-160.4 m), using anatomopathological WHO classification and St Jude (Murphy) estadification criteria.
Our patients mean age was 139 m (r: 5 m-211 m), with male predominance (59.7%). We evaluated the level of LDH at diagnosis with a mean of 1497 IU/L. The distribution according to histology was: BL 47.8%, DLCBL 20.9 %, LL 13.4 %, ALCL 11.9 % and others 4.5 %.
The distribution according to Murphy’s stadification was: I (3.1%), II (24.6%), III (60%), IV (10.8%) and IVZ (1.5%). The risk estadification as follows: 1 (1.5%), 2 (26.2%), 3 (69.2%), 4 (3.1%).
In DLCBL we observed a predominance of risks 1-2 (p: 0.015) and stages I-II (p: 0.023). In LL the most prevalent risks were 3-4 (p: 0.0128) and stages III-IV (p: 0.05). The more frequent locations were: abdominal 27%, cervical 10.4%, BM: 10,4%, mediastinal 10.4%, bone 10.4%, skin 10,4%, lung 7,5%, CNS 4.5% and liver 3%. BL had a significant correlation with abdominal and cervical location (p: <0.01), DCBL with cervical location (p: 0.043), LL with mediastinal location (p: <0.01) and ALCL with lung location (p: <0.01).
The global complete remission (CR) rate was: 91%. The event free survival (EFS) was 83 % at 12 months, 79% at 24 months and 77.9% at 36 months. Nine patients relapsed (14.8%), 3 early relapses and 6 late relapses. Overall survival rates were 89% at 12 months, 82% at 24 months and 79.1% at 36 months. EFS and OS were similar to the reported in the literature.
Currently there are new criteria available for stadification and prognosis of NHL.
References
2. Angelo Rosolen, Sherrie L, Perkins C, Pinkerton R et al: Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 33:2112-2118 2015.
3. Deepa Bhojwani, Mary Beth McCarville, John K. Choi et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol. 2015 March; 168(6): 845-853.
4. Véronique Minard-Colin, Laurence Brugières, Alfred Reiter et al. Non-Hodgkin Lymphoma in Children and Adolescents: Progress through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol. 2015;33:2963-2974.
5. Sally F. Barrington, N. George Mikhaeel, Lale Kostakoglu et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048-3058.
6. Bruce Shiramizu, Lara Mussolin, Wilhelm Woessmann, Wolfram Klappe. Paediatric non-Hodgkin lymphoma - perspectives in translational biology. Br J Haematol. 2016 May; 173(4): 617-624.
7. Sandlund, J.T. Non-Hodgkin lymphoma in children. Curr Hematol Malig Rep. 2015;10: 237.
8. Rodney R. Miles, Rikin K. Shah, J. Kimble Frazer. Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016 May; 173(4): 582-596.
9. Amthauer H, Furth C, Denecke T, Hundsdoerfer P, Voelker T, Seeger K, Stover B, Henze G. FDGPET in 10 children with non-Hodgkin’s lymphoma: initial experience in staging and follow-up. Klin Padiatr. 2005; 217:327-333.
10. Mody RJ, Bui C, Hutchinson RJ, Frey KA, Shulkin BL. Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma. 2007; 48:699-707.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar